|
Mabthera© eradicates lymphoma cells via the CD20 receptor and multiple mechanisms, including complement-mediated cytotoxicity (CDC), antibody-dependent cytotoxicity (ADCC) and apoptosis.
- Mabthera© directly binds to the C1q complement factor, initiating complement-mediated lysis of circulating B-cells4
- Additionally, Mabthera© binds strongly to Fc receptors on human effector cells, such as macrophages and natural killer cells, inducing ADCC to destroy lymphoma cells2
- Furthermore, Mabthera© demonstrates an effect on the proliferation and differentiation of malignant lymphoid cells, and cell cycle regulation1,3,5,6, as well as inducing apoptosis, or programmed cell death, in vitro2
REFERENCES
1. Li H, et al. J Biol Chem 2003; 278: 42427-42434.
2. Maloney DG, et al. Blood (ASH Annual Meeting Abstracts) 1996; 88 (Supplement 1): abs 637a.
3. Mathas S, et al. Cancer Res 2000; 60: 7170-7176.
4. Reff ME, et al. Blood 1994; 83: 435-445.
5. Riley JK, Sliwkowski MX. Semin Oncol 2000; 27: 17-24.
6. Shan D, et al. Cancer Immunol Immunother 2000; 48: 673- 683. |